<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="467">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04425837</url>
  </required_header>
  <id_info>
    <org_study_id>PLASMA COVID-19</org_study_id>
    <nct_id>NCT04425837</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19</brief_title>
  <official_title>Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19: A Randomized, Controlled Study CRI-CP (Coronavirus Investigation - Convalescent Plasma)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Santa Fe de Bogota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Santa Fe de Bogota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected the global&#xD;
      population with significant morbidity and mortality. One of the main concerns is the&#xD;
      management of the patients since there is no specific treatment for this condition.&#xD;
      Therefore, in SARS-CoV-2 patients the compassionate use of off-label therapies has been&#xD;
      initiated; such as the use of plasma from convalescent patients. This treatment has been used&#xD;
      in other pandemics like SARS-CoV-1, H5N1, H1N1, Ebola, among others. This study is a phase&#xD;
      II/III randomized clinical trial to assess the effectiveness and safety of convalescent&#xD;
      plasma administration in patients with high-risk SARS-CoV-2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II/III randomized clinical trial to assess the effectiveness and safety of&#xD;
      anti-SARS-CoV-2 convalescent plasma in i) hospitalized adult patients with high-risk of&#xD;
      progression SARS-CoV-2 infection and ii) patients in Intensive Care Unit (ICU).&#xD;
&#xD;
      Compatible ABO plasma from convalescent patients will be administered at a dose of 400 ml&#xD;
      divided into two doses intravenously. Outcomes will be measured as follows:&#xD;
&#xD;
      * Group of patients with critical illness:&#xD;
&#xD;
      Primary outcomes (Effectiveness and safety):&#xD;
&#xD;
        -  Mortality&#xD;
&#xD;
        -  Safety: Presence of adverse events&#xD;
&#xD;
      Secondary outcomes:&#xD;
&#xD;
        -  Intensive care unit length of stay&#xD;
&#xD;
        -  Evolution of clinical and paraclinical aspects.&#xD;
&#xD;
             -  Group of patients at high risk of progression:&#xD;
&#xD;
      Primary outcomes (Effectiveness and safety):&#xD;
&#xD;
        -  Mortality&#xD;
&#xD;
        -  Safety: Presence of adverse events&#xD;
&#xD;
        -  Admission to ICU in 30 days&#xD;
&#xD;
        -  Mechanical ventilation requirement&#xD;
&#xD;
      Secondary outcomes:&#xD;
&#xD;
        -  Hospital/Intensive care unit length of stay&#xD;
&#xD;
        -  Evolution of clinical and paraclinical aspects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>Up to 30 days after the study enrollment</time_frame>
    <description>Death of the patient (yes/no)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 30 days after the study enrollment</time_frame>
    <description>Presence of any of the following adverse events (yes/no):&#xD;
Nonhemolytic febrile reactions&#xD;
Allergic reactions&#xD;
Acute hemolytic reactions&#xD;
Non-immune hemolysis&#xD;
Acute transfusion-related lung damage&#xD;
Transfusion-related circulatory overload&#xD;
Metabolic reactions&#xD;
Hypotensive reactions&#xD;
Delayed hemolytic reactions&#xD;
Post transfusion purple&#xD;
Graft versus host disease&#xD;
Bacterial contamination of blood components&#xD;
Viral infections&#xD;
Other infections (syphilis, prions, malaria, Chagas, yellow fever, dengue)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ICU admission</measure>
    <time_frame>Up to 30 days after the study enrollment</time_frame>
    <description>Admitted to intensive care units (ICUs) (yes/no)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mechanical ventilation</measure>
    <time_frame>Up to 30 days after the study enrollment</time_frame>
    <description>Mechanical ventilation requirement (yes/no)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU length</measure>
    <time_frame>Up to 30 days after the study enrollment</time_frame>
    <description>Intensive care unit length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of D Dimer</measure>
    <time_frame>Assessment at day 30 after study enrollment</time_frame>
    <description>D dimer reduction below 1mcg / ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDH reduction</measure>
    <time_frame>Assessment at day 30 after study enrollment</time_frame>
    <description>Reduction of LDH below 350 IU / L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of Troponin level</measure>
    <time_frame>Assessment at day 30 after study enrollment</time_frame>
    <description>Reduction of troponin level to than 8 pg / mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in ferritin level</measure>
    <time_frame>Assessment at day 30 after study enrollment</time_frame>
    <description>Decrease in ferritin level below 1025 mcg / L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in procalcitonin level</measure>
    <time_frame>Assessment at day 30 after study enrollment</time_frame>
    <description>Decrease in procalcitonin level below 0.1ng / ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in CRP</measure>
    <time_frame>Assessment at day 30 after study enrollment</time_frame>
    <description>Decrease in CRP level bellow &lt;8 mg / L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in lymphocyte count</measure>
    <time_frame>Assessment at day 30 after study enrollment</time_frame>
    <description>Increase in lymphocyte count greater than 0.6 x 10-9 / L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in PaO2 / Fio2</measure>
    <time_frame>Assessment at day 30 after study enrollment</time_frame>
    <description>Increase in PaO2 / Fio2 greater than 200</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in Sequential Organ failure assessment (SOFA ) score</measure>
    <time_frame>Assessment at day 30 after study enrollment</time_frame>
    <description>Scale of 24 points, greater number indicates worst outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extracorporeal membrane oxygenation (ECMO)</measure>
    <time_frame>Assessment at day 30 after study enrollment</time_frame>
    <description>Extracorporeal membrane oxygenation requirement (ECMO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung infiltration</measure>
    <time_frame>Assessment at day 30 after study enrollment</time_frame>
    <description>Decrease in the percentage of lung infiltration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">236</enrollment>
  <condition>Sars-CoV2</condition>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>Standard care alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SARS-CoV-2 convalescent plasma treatment plus standard care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SARS-CoV-2 convalescent plasma treatment</intervention_name>
    <description>Plasma transfusion of convalescent patients from COVID-19 with negative RT-PCR, and antibody titers of 1:160 or greater at a dose of 400ml distributed in two doses administered on the same day intravenous administration</description>
    <arm_group_label>SARS-CoV-2 convalescent plasma treatment plus standard care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard care</intervention_name>
    <description>Standard care according to guidelines and national regulations</description>
    <arm_group_label>SARS-CoV-2 convalescent plasma treatment plus standard care</arm_group_label>
    <arm_group_label>Standard care alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All patients&#xD;
&#xD;
          -  Patients diagnosed with COVID-19 infection by RT-PCR technique&#xD;
&#xD;
          -  Patients ≥ 18 years of age&#xD;
&#xD;
          -  Patients in standard care according to the national guide&#xD;
&#xD;
          -  Onset of symptoms ≤ 14 days&#xD;
&#xD;
          -  Signature of informed consent report&#xD;
&#xD;
        Patients at high risk of progression, defined by all of the following:&#xD;
&#xD;
          -  Score greater than 9 on the CALL scale&#xD;
&#xD;
          -  Pao2 / Fio2 ≤ 200 (parameters adjusted to the height of Bogotá, Colombia)&#xD;
&#xD;
          -  X-ray or CT compatible with pneumonia&#xD;
&#xD;
          -  Hospitalized patients&#xD;
&#xD;
        Critically ill patients, defined by any of the following:&#xD;
&#xD;
          -  Mechanical ventilation requeriment&#xD;
&#xD;
          -  Patients in Intensive Care Unit or Intermediate Care Unit&#xD;
&#xD;
          -  Ventilatory failure, septic shock, dysfunction or multi-organ failure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Negative RT-PCR result from secretion 48 hours prior to study recruitment&#xD;
&#xD;
          -  History of allergic reaction to blood or plasma in patients with a known history of&#xD;
             IgA deficiency&#xD;
&#xD;
          -  Patients participating in other clinical trial&#xD;
&#xD;
          -  History of allergy to blood products&#xD;
&#xD;
          -  History of confirmed infection and that required antibiotic or antifungal treatment 30&#xD;
             days prior to recruitment&#xD;
&#xD;
          -  Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Guillermo E Quintero, Hematologist</last_name>
    <phone>5716030303</phone>
    <phone_ext>1221</phone_ext>
    <email>quiquequintero@yahoo.com.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>José A De la Hoz, Epidemiologist</last_name>
    <phone>5716030303</phone>
    <phone_ext>1127</phone_ext>
    <email>jose.delahoz@fsfb.org.co</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fundación Santa Fe de Bogotá</name>
      <address>
        <city>Bogotá</city>
        <state>Cundinamarca</state>
        <zip>110111</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <contact>
      <last_name>José De la Hoz, Epidemiologist</last_name>
      <phone>5716030303</phone>
      <phone_ext>1127</phone_ext>
      <email>jose.delahoz@fsfb.org.co</email>
    </contact>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 29, 2020</study_first_submitted>
  <study_first_submitted_qc>June 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación Santa Fe de Bogota</investigator_affiliation>
    <investigator_full_name>Guillermo Enrique Quintero-Vega</investigator_full_name>
    <investigator_title>Hematologist</investigator_title>
  </responsible_party>
  <keyword>COVID-19 serotherapy</keyword>
  <keyword>Mortality</keyword>
  <keyword>Safety</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

